TASMAN PHARMA

Serial Number 90237013
Registration 7530788
700

Registration Progress

Application Filed
Oct 6, 2020
Under Examination
Jun 8, 2021
Approved for Publication
Apr 13, 2021
Published for Opposition
Apr 13, 2021
Registered
Oct 8, 2024

Basic Information

Serial Number
90237013
Registration Number
7530788
Filing Date
October 6, 2020
Registration Date
October 8, 2024
Published for Opposition
April 13, 2021
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Oct 8, 2024
Registration
Registered
Classes
005

Rights Holder

Douglas Pharmaceuticals Limited

03
Address
Central Park Drive
Lincoln, Auckland 0610
NZ

Ownership History

Douglas Pharmaceuticals Limited

Original Applicant
03
Lincoln, Auckland NZ

Douglas Pharmaceuticals Limited

Owner at Publication
03
Lincoln, Auckland NZ

Douglas Pharmaceuticals Limited

Original Registrant
03
Lincoln, Auckland NZ

Legal Representation

Attorney
Christopher D. Olszyk, Jr.

USPTO Deadlines

Next Deadline
1917 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-10-08)
Due Date
October 08, 2030
Grace Period Ends
April 08, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

36 events
Date Code Type Description
Oct 8, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 8, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER
Sep 1, 2024 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 1, 2024 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 28, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE
May 27, 2024 IUAF S USE AMENDMENT FILED
May 27, 2024 EISU I TEAS STATEMENT OF USE RECEIVED
Dec 15, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 14, 2023 EX5G S SOU EXTENSION 5 GRANTED
Dec 13, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 4, 2023 EXT5 S SOU EXTENSION 5 FILED
Dec 4, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 9, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 6, 2023 EX4G S SOU EXTENSION 4 GRANTED
Jun 6, 2023 EXT4 S SOU EXTENSION 4 FILED
Jun 6, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Dec 9, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 7, 2022 EX3G S SOU EXTENSION 3 GRANTED
Dec 7, 2022 EXT3 S SOU EXTENSION 3 FILED
Dec 7, 2022 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 7, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 3, 2022 EX2G S SOU EXTENSION 2 GRANTED
Jun 3, 2022 EXT2 S SOU EXTENSION 2 FILED
Jun 3, 2022 EEXT I SOU TEAS EXTENSION RECEIVED
Nov 24, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 22, 2021 EX1G S SOU EXTENSION 1 GRANTED
Nov 22, 2021 EXT1 S SOU EXTENSION 1 FILED
Nov 22, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 8, 2021 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 13, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 13, 2021 PUBO A PUBLISHED FOR OPPOSITION
Mar 24, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 9, 2021 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 5, 2021 DOCK D ASSIGNED TO EXAMINER
Nov 19, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 9, 2020 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the prevention and treatment of psychiatric diseases and disorders
First Use Anywhere: 20240100
First Use in Commerce: 20240100

Additional Information

Pseudo Mark
TASMAN PHARMACEUTICAL

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMA"